2566 Stock Overview
Hangzhou Jiuyuan Gene Engineering Co., Ltd. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 2566 from our risk checks.
Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$6.52 |
| 52 Week High | HK$9.10 |
| 52 Week Low | HK$5.18 |
| Beta | 0 |
| 1 Month Change | 1.72% |
| 3 Month Change | 4.82% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -14.77% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2566 | HK Pharmaceuticals | HK Market | |
|---|---|---|---|
| 7D | -8.9% | 4.3% | -1.7% |
| 1Y | n/a | 16.6% | 24.2% |
Return vs Industry: Insufficient data to determine how 2566 performed against the Hong Kong Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how 2566 performed against the Hong Kong Market.
Price Volatility
| 2566 volatility | |
|---|---|
| 2566 Average Weekly Movement | 7.1% |
| Pharmaceuticals Industry Average Movement | 6.1% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in HK Market | 14.1% |
| 10% least volatile stocks in HK Market | 3.4% |
Stable Share Price: 2566 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: Insufficient data to determine 2566's volatility change over the past year.
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 1,541 | Hang Fu | www.china-gene.com |
Hangzhou Jiuyuan Gene Engineering Co., Ltd. engages in the research, development, production and sales of biopharmaceutical products and medical devices. It offers Guyoudao, a recombinant human bone morphogenetic protein-2 (rhBMP-2) bone repair product; Jilifen, a Human granulocyte colony stimulating factor injection for neutropenia; and Jijufen, a human interleukin-11 injection for chemotherapy-induced thrombocytopenia.
Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. Fundamentals Summary
| 2566 fundamental statistics | |
|---|---|
| Market cap | HK$1.60b |
| Earnings (TTM) | HK$147.95m |
| Revenue (TTM) | HK$1.46b |
10.8x
P/E Ratio1.1x
P/S RatioIs 2566 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2566 income statement (TTM) | |
|---|---|
| Revenue | CN¥1.37b |
| Cost of Revenue | CN¥287.51m |
| Gross Profit | CN¥1.08b |
| Other Expenses | CN¥943.08m |
| Earnings | CN¥138.60m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.56 |
| Gross Margin | 79.00% |
| Net Profit Margin | 10.12% |
| Debt/Equity Ratio | 7.9% |
How did 2566 perform over the long term?
See historical performance and comparisonDividends
0.9%
Current Dividend Yield8%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/04/03 09:55 |
| End of Day Share Price | 2025/04/03 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.